Resources - general public
ATAGI strategic intent
The strategic intent of the Australian Technical Advisory Group on Immunisation (ATAGI) includes their vision, purpose, priorities and principles.
Protocols for National Action to Respond to Adverse Events Following Immunisation
Vaccines are safe and effective, but adverse reactions can occur. These protocols outline what to do in the case of a serious adverse event following immunisation, including roles, responsibilities and timelines for action.
The COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group Terms of reference
The terms of reference sets out the role and purpose of the COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group.
Australia’s COVID-19 Vaccine and Treatment Strategy
Our COVID-19 Vaccine and Treatment Strategy outlines how we are investing in promising vaccines and treatments and how they will be safely, fairly and rapidly delivered to Australians.
ATAGI 75th meeting agenda – 18 June 2020
Australian Technical Advisory Group on Immunisation (ATAGI) agenda for the 75th meeting held on 18 June 2020.
ATAGI clinical advice on hepatitis A vaccine
This resource provides advice for immunisation providers regarding the administration of hepatitis A vaccine.
ATAGI clinical advice on vaccination recommendations for people with risk conditions from 1 July 2020
This resource provides clinical advice for immunisation providers on changes to vaccine recommendations and funding for people with risk conditions from 1 July 2020.
ATAGI clinical advice on changes to recommendations for meningococcal vaccines from 1 July 2020
This resource provides advice for immunisation providers on changes to recommendations for the use and funding of meningococcal vaccines from 1 July 2020.
ATAGI clinical advice on changes to recommendations for pneumococcal vaccines from 1 July 2020
This resource provides advice for immunisation providers on changes to recommendations for the use and funding of pneumococcal vaccines from 1 July 2020.
ATAGI clinical advice on vaccine recommendations for older non-Indigenous adults from 1 July 2020
This resource provides advice for immunisation providers on changes to vaccine recommendations and funding for older non-Indigenous adults from 1 July 2020.
ATAGI clinical advice on vaccination recommendations for Aboriginal and Torres Strait Islander people from 1 July 2020
This resource provides clinical advice for immunisation providers on changes to vaccine recommendations and funding for Aboriginal and Torres Strait Islander people from 1 July 2020.
National Immunisation Program – Meningococcal vaccination schedule from 1 July 2020 – Clinical advice for vaccination providers
This fact sheet provides clinical advice for vaccination providers on changes to meningococcal vaccination on the National Immunisation Program schedule from 1 July 2020.
Vaccinate to protect your baby against meningococcal B – brochure for Aboriginal and Torres Strait Islander people
This brochure provides information for Aboriginal and Torres Strait Islander parents and carers about getting their child vaccinated against meningococcal B disease.
Free meningococcal B vaccine – poster for Aboriginal and Torres Strait Islander people
This poster provides information for Aboriginal and Torres Strait Islander people about the meningococcal B vaccine for infants, and can be used in health care and community settings.
ATAGI Guiding Principles for maintaining immunisation services during COVID-19 pandemic
Guiding Principles for maintaining immunisation services during the COVID-19 pandemic.
Adolescent meningococcal ACWY vaccine – brochure for Aboriginal and Torres Strait Islander peoples
This brochure includes information for Aboriginal and Torres Strait Islander peoples about the meningococcal ACWY vaccine, available free for adolescents.
ATAGI advice on seasonal influenza vaccines in 2020
This resource provides advice for immunisation providers regarding the administration of 2020 seasonal influenza vaccines.
Adolescent ‘booster’ dose of diphtheria-tetanus-pertussis (dTpa) vaccine - brochure
This brochure provides information about the diphtheria-tetanus-pertussis (dTpa) vaccine for adolescents.
National HPV vaccination coverage by dose number for adolescents by age group
Historical reports showing national human papillomavirus (HPV) vaccination coverage by dose number (1, 2 or 3) and age group.
National HPV vaccination coverage by remoteness
Historical reports showing national human papillomavirus (HPV) vaccination coverage by remoteness of the area of residence.
Historical Human Papillomavirus (HPV) immunisation coverage rates
Historical reports showing vaccination coverage with 3 doses of human papillomavirus (HPV) vaccine for adolescents turning 15 years of age by year for each state and territory.
National HPV 3 dose vaccination coverage for all adolescents turning 15 years of age from year of program commencement
Historical reports shows vaccination coverage with 3 doses of human papillomavirus (HPV) vaccine for male and female adolescents turning 15 years of age.
National HPV vaccination coverage by socio-economic status
Historical reports showing national human papillomavirus (HPV) vaccination coverage by the socio-economic status of the area of residence.
National HPV vaccination coverage for the female catch up cohort by year of age
Historical reports showing national human papillomavirus (HPV) vaccination coverage for the the female catch up cohort by dose number (1, 2 or 3) and single age cohort (12-26 years) for the specified year.
Vaccine safety in Australia AusVaxSafety summary report 2018
AusVaxSafety is a national system monitoring vaccine safety in Australia. The report shows how people receiving vaccines, or their parents and carers, responded to the SMS about their health a few days after vaccination at each schedule point in the National Immunisation Program in Australia 2018.
Date last updated: